<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00597376</url>
  </required_header>
  <id_info>
    <org_study_id>Pamlab-Cerefolin NAC-001-01</org_study_id>
    <nct_id>NCT00597376</nct_id>
  </id_info>
  <brief_title>Study of the Effects of Cerefolin NAC on Inflammation Blood Markers in Older Individuals With Memory Complaints</brief_title>
  <official_title>A Six-month, Double-blind, Placebo-controlled, Single Site Study of Cerefolin NAC on Blood Homocysteine, Oxidative Stress, and Beta-amyloid Biomarkers That May Potentiate Inflammation and Neuronal Damage in Older Individuals With Memory Complaints Who Have Not Been Clinically Diagnosed With Mild Cognitive Impairment, Vascular Dementia, or Alzheimer's Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rush University Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Pamlab, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Rush University Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this six-month research study is to determine if Cerefolin NAC reduces levels
      of substances in the blood that may be associated with thinking ability and the health of
      brain cells in subjects with memory concerns when compared to a standard multivitamin.
      Cerefolin NAC is available as a dietary supplement via a prescription from a physician. The
      multivitamin used in the study contains the Recommended Daily Intake recommended for older
      persons.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study Phase: Exploratory

      Indication: Memory Complaints

      Study Design:

      A single-center, double-blind, placebo-controlled study with 100 subjects with memory
      complaints followed for 6 months (4 visits)using Cerefolin® NAC or placebo once a day in
      addition to a standardized multivitamin.

      Sample Size:

      100 subjects as follows:

        1. 50 on Cerefolin® NAC + multivitamin; and,

        2. 50 on Placebo + multivitamin.

      Primary Objective:

      To determine if Cerefolin® NAC (compared to multivitamin) decreases the blood level of
      homocysteine, increases the blood level of glutathione (a marker for oxidative stress), and
      increases the ratio of Aβ42 to Aβ40 (a marker for beta-amyloid) that may be related to
      neuronal injury and inflammation.

      Secondary Objectives:

        1. To determine if Cerefolin® NAC reduces hs-CRP and TNF-α blood levels, and increases IL-6
           blood levels.

        2. To determine if Cerefolin® NAC (compared to Placebo) reduces plasma F2 isoprostane and
           increases potential antioxidant (PAO) levels.

        3. To assess the tolerability of Cerefolin® NAC

        4. To explore the effects of Cerefolin® NAC on a 6-month change in: (a)global and specific
           cognitive domains in a standardized neuropsychological test battery,(b) quality of life
           as measured by SF-36, (c)instrumental and basic activities of daily living, (d)MADRS;
           and (e)performance-based physical function.

        5. To explore if a change in homocysteine level is related to a change in the plasma
           glutathione, hs-CRP, IL-6, TNF-α, F2-isoprostane, and PAO levels and to a change in the
           ratio of Aβ42 to Aβ40.

        6. To explore the effects of MS AG2756, APOE and MFTHR on the relationship examined in
           Secondary Objective #5.

        7. To explore the relationship of B12 status and status to cognition

      NOTE: For individuals successfully completing the 6-month blinded phase, there is an 12-month
      open-label extension of Cerefolin NAC + multivitamin. The primary purpose of the exploratory,
      open-label extension phase of the CERE-001 study is to systematically collect long-term
      safety data on CEREFOLIN NAC usage over an additional 12-month period.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2007</start_date>
  <completion_date type="Actual">May 2011</completion_date>
  <primary_completion_date type="Actual">May 2011</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Six Month Blood Levels of Homocysteine, Glutathione, and the Ratio of Aβ42 to Aβ40 (as a Percent of Baseline Levels) After Daily Intake of Cerefolin NAC Plus a Multivitamin Versus a Multivitamin Only</measure>
    <time_frame>6 months</time_frame>
    <description>Primary outcome markers were plasma homocysteine (tHcy), glutathione, and the ratio of amyloid proteins, Aβ42 and Aβ40. Plasma tHcy and glutathione were assayed using a high performance liquid chromatography (HPLC) with fluorescence detection method. Enzyme-linked immunosorbent assays (ELISA) were used for Aβ42 (Wako Chemicals USA, Inc., Richmond, VA) and Aβ40 (Invitrogen Corporation, Canarillo, CA) detection. Primary analyses utilized Last Observation Carried Forward (LOCF) to assess the primary biomarker level at 6 months versus baseline. Six month levels in biomarker outcomes were compared using t-tests of the logarithmically transformed values and the antilogarithm was applied to the SDs obtain 95% confidence intervals (95% CIs). A significant difference between treatments was needed for at least one of the primary outcome variables (tHcy, glutathione, or the Aβ42 to Aβ40 ratio) to declare the study positive.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Tolerability of Cerefolin NAC and a Multivitamin Versus a Multivitamin Only</measure>
    <time_frame>6 months</time_frame>
    <description>Mean study product compliance was measured as the actual number of study product tablets taken as a percent of the maximum study product tablets that could have been taken during the intervention period.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Six Month Levels of Inflammation and Oxidative Stress Markers(as a Percent of Baseline Levels) After Daily Treatment With Cerefolin NAC and a Multivitamin or a Multivitamin Only</measure>
    <time_frame>6 months</time_frame>
    <description>Outcome measures were 6-month levels of highly sensitive c-reactive protein (hs-CRP), tumor necrosis factor alpha (TNF-alpha), interleukin-6 (IL-6), malondialdehyde, and potential anti-oxidant (PAO)in blood samples as a percent of baseline value.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">104</enrollment>
  <condition>Subjective Memory Loss in Older Persons</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>On Cerefolin NAC and open-label multivitamin supplement</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>On placebo and open label multivitamin supplement</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Cerefolin NAC (a medical food)</intervention_name>
    <description>Cerefolin NAC one tablet each day</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Cerefolin NAC placebo</intervention_name>
    <description>Placebo tablet once a day</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age greater than 60;

          -  Memory complaints as defined by two questions:

               1. &quot;Do The subject think your have memory problems?&quot;; and,

               2. &quot;Has there been a decline in your memory over the last 10 years?&quot;

          -  Fluency in English;

          -  Ability to ingest oral medications; and,

          -  Willing to replace current vitamin intake with a standardized multivitamin provided
             for the study.

        Exclusion Criteria:

          -  Clinical stroke or Parkinson's disease;

          -  Taking FDA approved drug for symptomatic treatment of Alzheimer's disease (Aricept,
             Razadyne, Exelon, and/or Namenda);

          -  History of significant renal insufficiency (creatinine ≥1.5);

          -  History of renal stones or peptic ulcer disease;

          -  Use of vitamin supplements containing more than 400mcg of folic acid per day within 2
             months of Screen Visit;

          -  As determined by the study physician, clinically significant serum folate and vitamin
             B12 deficiency on screening blood tests that would require further clinical evaluation
             and treatment

          -  As determined by the study physician, clinically significant medical conditions,
             physical exam findings or abnormal blood tests at screening that would require further
             clinical evaluation and treatment

          -  B12 injections 6 months prior to the Screen Visit;

          -  Confirmed clinical diagnosis of Mild Cognitive Impairment (MCI), vascular dementia or
             Alzheimer's Disease (AD); and,

          -  Known hypersensitivity to L-methylfolate, methyl-cobalamin or N-acetylcysteine.

          -  Use of any other investigational agent used during the 30 days prior to Screening.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>60 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Raj C Shah, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Rush University Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Rush Alzheimer's Disease Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.rush.edu/radc</url>
    <description>Rush Alzheimer's Disease Center</description>
  </link>
  <verification_date>May 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 9, 2008</study_first_submitted>
  <study_first_submitted_qc>January 9, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 18, 2008</study_first_posted>
  <results_first_submitted>January 25, 2013</results_first_submitted>
  <results_first_submitted_qc>May 20, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">May 23, 2013</results_first_posted>
  <last_update_submitted>May 20, 2013</last_update_submitted>
  <last_update_submitted_qc>May 20, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 23, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Rush University Medical Center</investigator_affiliation>
    <investigator_full_name>Raj C Shah</investigator_full_name>
    <investigator_title>Assistant Professor, Family Medicine and Rush Alzheimer's Disease Center</investigator_title>
  </responsible_party>
  <keyword>memory loss</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Inflammation</mesh_term>
    <mesh_term>Memory Disorders</mesh_term>
    <mesh_term>Amnesia</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Between March 2008 and September 2009, persons expressing study interest at community presentations or at the Rush Memory Clinic were contacted. Of 524 persons expressing interest, 400 were excluded before consenting for having excluding clinical diagnoses(227), participation refusal (119), and other exclusions medication (54).</recruitment_details>
      <pre_assignment_details>Consented participants underwent a screening evaluation to ensure inclusion criteria were met prior to study treatment assignment and one month run-in treatment with a multivitamin only. Of 124 consented individuals, 20 discontinued prior to randomization due to new medical conditions (9), declining participation (5), and for other reasons (6).</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Cerefolin NAC + Multivitamin</title>
          <description>On Cerefolin NAC and open-label multivitamin supplement
Cerefolin NAC (a medical food) : Cerefolin NAC one tablet each day</description>
        </group>
        <group group_id="P2">
          <title>Cerefolin NAC Placebo + Multivitamin</title>
          <description>On placebo and open label multivitamin supplement
Cerefolin NAC placebo : Placebo tablet once a day</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="51"/>
                <participants group_id="P2" count="53"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="43">All participants started (51) were included in primary analyses.</participants>
                <participants group_id="P2" count="49">All participants started (53) were included in primary analyses.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Cerefolin NAC + Multivitamin</title>
          <description>On Cerefolin NAC and open-label multivitamin supplement
Cerefolin NAC (a medical food) : Cerefolin NAC one tablet each day</description>
        </group>
        <group group_id="B2">
          <title>Cerefolin NAC Placebo + Multivitamin</title>
          <description>On placebo and open label multivitamin supplement
Cerefolin NAC placebo : Placebo tablet once a day</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="51"/>
            <count group_id="B2" value="53"/>
            <count group_id="B3" value="104"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="80.9" spread="6.6"/>
                    <measurement group_id="B2" value="79.4" spread="8.7"/>
                    <measurement group_id="B3" value="80.1" spread="7.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="46"/>
                    <measurement group_id="B2" value="42"/>
                    <measurement group_id="B3" value="88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="51"/>
                    <measurement group_id="B2" value="53"/>
                    <measurement group_id="B3" value="104"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Education Level</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15" spread="3"/>
                    <measurement group_id="B2" value="15" spread="3"/>
                    <measurement group_id="B3" value="15" spread="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>total plasma homocysteine</title>
          <units>micromol/L</units>
          <param>Geometric Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8.35" spread="1.32"/>
                    <measurement group_id="B2" value="8.10" spread="1.33"/>
                    <measurement group_id="B3" value="8.22" spread="1.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>glutathione</title>
          <units>micromol/L</units>
          <param>Geometric Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4.01" spread="1.67"/>
                    <measurement group_id="B2" value="4.02" spread="1.59"/>
                    <measurement group_id="B3" value="4.02" spread="1.63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>ratio of amyloid beta 1-42 to 1-40</title>
          <units>pmol/L:pmol/L</units>
          <param>Geometric Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0.027" spread="1.73"/>
                    <measurement group_id="B2" value="0.034" spread="1.81"/>
                    <measurement group_id="B3" value="0.031" spread="1.77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>highly sensitive c-Reactive Protein</title>
          <units>mg/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0.20" spread="18.93"/>
                    <measurement group_id="B2" value="0.23" spread="22.37"/>
                    <measurement group_id="B3" value="0.22" spread="20.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>tumor necrosis factor alpha</title>
          <units>pg/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1.45" spread="1.61"/>
                    <measurement group_id="B2" value="1.37" spread="1.53"/>
                    <measurement group_id="B3" value="1.41" spread="1.57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>interleukin-6</title>
          <units>pg/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2.12" spread="1.98"/>
                    <measurement group_id="B2" value="2.12" spread="2.35"/>
                    <measurement group_id="B3" value="2.12" spread="2.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>malondialdehyde</title>
          <units>micromol/L</units>
          <param>Geometric Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0.90" spread="1.67"/>
                    <measurement group_id="B2" value="0.93" spread="1.75"/>
                    <measurement group_id="B3" value="0.92" spread="1.71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>potential anti-oxidant (PAO)</title>
          <description>Potential anti-oxidant (PAO) measures the antioxidant capacity of a serum sample to reduce cupric ions from Cu++ to Cu+.</description>
          <units>micromol/L</units>
          <param>Geometric Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="979" spread="2"/>
                    <measurement group_id="B2" value="1016" spread="2"/>
                    <measurement group_id="B3" value="997" spread="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Six Month Blood Levels of Homocysteine, Glutathione, and the Ratio of Aβ42 to Aβ40 (as a Percent of Baseline Levels) After Daily Intake of Cerefolin NAC Plus a Multivitamin Versus a Multivitamin Only</title>
        <description>Primary outcome markers were plasma homocysteine (tHcy), glutathione, and the ratio of amyloid proteins, Aβ42 and Aβ40. Plasma tHcy and glutathione were assayed using a high performance liquid chromatography (HPLC) with fluorescence detection method. Enzyme-linked immunosorbent assays (ELISA) were used for Aβ42 (Wako Chemicals USA, Inc., Richmond, VA) and Aβ40 (Invitrogen Corporation, Canarillo, CA) detection. Primary analyses utilized Last Observation Carried Forward (LOCF) to assess the primary biomarker level at 6 months versus baseline. Six month levels in biomarker outcomes were compared using t-tests of the logarithmically transformed values and the antilogarithm was applied to the SDs obtain 95% confidence intervals (95% CIs). A significant difference between treatments was needed for at least one of the primary outcome variables (tHcy, glutathione, or the Aβ42 to Aβ40 ratio) to declare the study positive.</description>
        <time_frame>6 months</time_frame>
        <population>The Intent-to-Treat (ITT) cohort included randomized subjects taking at least one study treatment dose. Primary analyses utilized Last Observation Carried Forward (LOCF) to assess 6 month levels in the primary biomarkers. 2-sided, t-test p-value for group differences was only significant (&lt;0.05) for 6-month homocysteine level.</population>
        <group_list>
          <group group_id="O1">
            <title>Cerefolin NAC + Multivitamin</title>
            <description>On Cerefolin NAC and open-label multivitamin supplement</description>
          </group>
          <group group_id="O2">
            <title>Cerefolin NAC Placebo + Multivitamin</title>
            <description>On placebo and open-label multivitamin supplement</description>
          </group>
        </group_list>
        <measure>
          <title>Six Month Blood Levels of Homocysteine, Glutathione, and the Ratio of Aβ42 to Aβ40 (as a Percent of Baseline Levels) After Daily Intake of Cerefolin NAC Plus a Multivitamin Versus a Multivitamin Only</title>
          <description>Primary outcome markers were plasma homocysteine (tHcy), glutathione, and the ratio of amyloid proteins, Aβ42 and Aβ40. Plasma tHcy and glutathione were assayed using a high performance liquid chromatography (HPLC) with fluorescence detection method. Enzyme-linked immunosorbent assays (ELISA) were used for Aβ42 (Wako Chemicals USA, Inc., Richmond, VA) and Aβ40 (Invitrogen Corporation, Canarillo, CA) detection. Primary analyses utilized Last Observation Carried Forward (LOCF) to assess the primary biomarker level at 6 months versus baseline. Six month levels in biomarker outcomes were compared using t-tests of the logarithmically transformed values and the antilogarithm was applied to the SDs obtain 95% confidence intervals (95% CIs). A significant difference between treatments was needed for at least one of the primary outcome variables (tHcy, glutathione, or the Aβ42 to Aβ40 ratio) to declare the study positive.</description>
          <population>The Intent-to-Treat (ITT) cohort included randomized subjects taking at least one study treatment dose. Primary analyses utilized Last Observation Carried Forward (LOCF) to assess 6 month levels in the primary biomarkers. 2-sided, t-test p-value for group differences was only significant (&lt;0.05) for 6-month homocysteine level.</population>
          <units>percent of baseline level</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="51"/>
                <count group_id="O2" value="53"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>6-Month Homocysteine Level</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="71" lower_limit="66" upper_limit="77"/>
                    <measurement group_id="O2" value="101" lower_limit="96" upper_limit="107"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6-Month Glutathione Level</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="115" lower_limit="101" upper_limit="129"/>
                    <measurement group_id="O2" value="101" lower_limit="85" upper_limit="117"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6-Month AB42/AB40 Ratio</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="101" lower_limit="92" upper_limit="110"/>
                    <measurement group_id="O2" value="104" lower_limit="97" upper_limit="108"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Tolerability of Cerefolin NAC and a Multivitamin Versus a Multivitamin Only</title>
        <description>Mean study product compliance was measured as the actual number of study product tablets taken as a percent of the maximum study product tablets that could have been taken during the intervention period.</description>
        <time_frame>6 months</time_frame>
        <population>All participants in Intent-to-Treat cohort were included.</population>
        <group_list>
          <group group_id="O1">
            <title>Cerefolin NAC + Multivitamin</title>
            <description>On Cerefolin NAC and open-label multivitamin supplement</description>
          </group>
          <group group_id="O2">
            <title>Cerefolin NAC Placebo + Multivitamin</title>
            <description>On placebo and open-label multivitamin supplement</description>
          </group>
        </group_list>
        <measure>
          <title>Tolerability of Cerefolin NAC and a Multivitamin Versus a Multivitamin Only</title>
          <description>Mean study product compliance was measured as the actual number of study product tablets taken as a percent of the maximum study product tablets that could have been taken during the intervention period.</description>
          <population>All participants in Intent-to-Treat cohort were included.</population>
          <units>percent of study drug taken</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="51"/>
                <count group_id="O2" value="53"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="88" spread="15"/>
                    <measurement group_id="O2" value="88" spread="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Six Month Levels of Inflammation and Oxidative Stress Markers(as a Percent of Baseline Levels) After Daily Treatment With Cerefolin NAC and a Multivitamin or a Multivitamin Only</title>
        <description>Outcome measures were 6-month levels of highly sensitive c-reactive protein (hs-CRP), tumor necrosis factor alpha (TNF-alpha), interleukin-6 (IL-6), malondialdehyde, and potential anti-oxidant (PAO)in blood samples as a percent of baseline value.</description>
        <time_frame>6 months</time_frame>
        <population>All participants in Intent-to-Treat were included with last observation carried forward.</population>
        <group_list>
          <group group_id="O1">
            <title>Cerefolin NAC + Multivitamin</title>
            <description>On Cerefolin NAC and open-label multivitamin supplement</description>
          </group>
          <group group_id="O2">
            <title>Cerefolin NAC Placebo + Multivitamin</title>
            <description>On placebo and open-label multivitamin supplement</description>
          </group>
        </group_list>
        <measure>
          <title>Six Month Levels of Inflammation and Oxidative Stress Markers(as a Percent of Baseline Levels) After Daily Treatment With Cerefolin NAC and a Multivitamin or a Multivitamin Only</title>
          <description>Outcome measures were 6-month levels of highly sensitive c-reactive protein (hs-CRP), tumor necrosis factor alpha (TNF-alpha), interleukin-6 (IL-6), malondialdehyde, and potential anti-oxidant (PAO)in blood samples as a percent of baseline value.</description>
          <population>All participants in Intent-to-Treat were included with last observation carried forward.</population>
          <units>percent of baseline level</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="51"/>
                <count group_id="O2" value="53"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>6-month hs-CRP Level</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="110" lower_limit="51" upper_limit="238"/>
                    <measurement group_id="O2" value="111" lower_limit="53" upper_limit="234"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6-month TNF-alpha Level</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99" lower_limit="93" upper_limit="106"/>
                    <measurement group_id="O2" value="108" lower_limit="98" upper_limit="118"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6-month IL-6 Level</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="114" lower_limit="97" upper_limit="134"/>
                    <measurement group_id="O2" value="105" lower_limit="88" upper_limit="125"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6-month Malondialdehyde Level</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="93" lower_limit="83" upper_limit="104"/>
                    <measurement group_id="O2" value="90" lower_limit="79" upper_limit="102"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6-month PAO Level</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="109" lower_limit="96" upper_limit="123"/>
                    <measurement group_id="O2" value="115" lower_limit="100" upper_limit="131"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Cerefolin NAC + Multivitamin</title>
          <description>On Cerefolin NAC and open-label multivitamin supplement</description>
        </group>
        <group group_id="E2">
          <title>Cerefolin NAC Placebo + Multivitamin</title>
          <description>On placebo and open-label multivitamin supplement</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="51"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="53"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiac disorders</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="51"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="53"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastrointestinal disorders</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="51"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="53"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>General Disorders</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="51"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="53"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Metabolism and nutrition disorders</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="53"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Musculoskeletal and connective tissue disorders</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="53"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Nervous system disorders</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="53"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal and urinary disorders</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="51"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="53"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Respiratory, thoracic and mediastinal disorders</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="53"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>1</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="30" subjects_at_risk="51"/>
                <counts group_id="E2" subjects_affected="28" subjects_at_risk="53"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiac disorders</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="53"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Eye disorders</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="53"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastrointestinal disorders</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="51"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="53"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>General disorders</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="51"/>
                <counts group_id="E2" events="7" subjects_affected="5" subjects_at_risk="53"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Metabolism and nutrition disorders</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="53"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Musculoskeletal and connective tissue disorders</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="51"/>
                <counts group_id="E2" events="7" subjects_affected="6" subjects_at_risk="53"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Nervous system disorders</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="51"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="53"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal and urinary disorders</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="53"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Respiratory, thoracic and mediastinal disorders</sub_title>
                <counts group_id="E1" events="7" subjects_affected="6" subjects_at_risk="51"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="53"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Skin and subcutaneous tissue disorders</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="51"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="53"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>No limitations or caveats to report.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Raj C. Shah, MD</name_or_title>
      <organization>Rush University Medical Center</organization>
      <phone>312-563-2902</phone>
      <email>Raj_C_Shah@rush.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

